All J&J articles
-
BusinessDrug companies reluctantly accept state price negotiations
As legal challenges fall flat, will industry’s claims of stifled innovation be borne out?
-
BusinessJ&J subsidiary sues more talc researchers
Lawsuit claims another study linking talc use to cancer is fraudulent
-
BusinessJ&J proposes to pay nearly $9 billion to settle talc lawsuits
Company re-files for bankruptcy of a subsidiary in the hopes of resolving tens of thousands of claims its products caused cancer
-
BusinessJ&J subsidiary claims key talc research is fraudulent
Complaint alleges study that helped link talc to cancer contained false information
-
BusinessJ&J to phase out talc-based baby powder worldwide
In the face of thousands of lawsuits, firm will switch to cornstarch-based formulations
-
BusinessHaleon emerges from GSK consumer healthcare spin-off
Split illustrates move towards narrower focus in pharmaceuticals
-
BusinessNew J&J subsidiary to absorb talc lawsuit liabilities
Firm aims to use bankruptcy protection and a $2bn trust to resolve thousands of cancer claims
-
BusinessUS supreme court will not hear J&J talc appeal
Decision means J&J must pay $2.1 billion previously awarded to 22 women who say talc caused their ovarian cancer
-
BusinessCovid vaccination efforts bolstered by trial results from J&J and Novavax
A miserable January ended with positive news on the vaccine front but new variants added complications
-
OpinionLooking beyond the next wave
We need to apply lessons from Covid-19 to tackle antimicrobial resistance and climate change
-
BusinessFrom philanthropy to sustainability
Corporate Social Responsibility in the pharmaceutical and chemical industries is changing
-
BusinessLandmark ruling in Oklahoma opioid lawsuit
J&J judged responsible for ‘public nuisance’ in first case to go to trial
-
OpinionShow me the data
Making industrial safety research more transparent benefits both companies and consumers
-
NewsWhy jury verdicts get overruled in US industry cancer trials
Judges often end up intervening post-trial in complex cases with conflicting scientific evidence
-
BusinessJ&J hit with bill for $4.7 billion in damages over talcum powder cancer link
Pharmaceutical and consumer goods giant loses another talc court case to 22 ovarian cancer patients
-
BusinessJ&J and the question of shadow research
Former academic researcher who found that talc is not carcinogenic admits that J&J funded his work, but says that fact is immaterial
-
BusinessBayer and J&J lose first blood thinner lawsuit
US jury fines Xarelto makers $27.8 million for downplaying drug risks
-
BusinessJudges overturn J&J talc cancer claims
Two new rulings follow trend of reversing large jury-awarded damages as firm works through thousands of cases
-
BusinessLong road to recovery for Puerto Rico pharmaceuticals
As inhabitants begin to rebuild their lives after the devastation of hurricane Maria, the island’s drug manufacturers are recovering slowly
-
BusinessAmgen partners to launch biosimilars in China
US biopharma and Chinese generics firm will co-develop medicines from Amgen’s pipeline focused on inflammation and oncology